Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback